I agree that the MSLT-2 trial is going to change who gets completion lymph node dissections, this may influence the use of Adjuvant Nivolumab in high risk IIIA that don’t undergo a completion lymph node dissection. Will be interesting to see how these decisions are made in these patients and of surgeons will have more of influence on the decision.

Latest Activity